Abstract: A formulation comprising: a co-polyester comprising (a) the reaction product of a polycondensation polyester and (b) glycolide; wherein the polycondensation polyester comprises the reaction product of diglycolic acid and/or a derivative thereof and ethylene glycol, and the co-polyester comprises about 40% by weight of the polycondensation polyester based on the total weight of the co-polyester; and a drug selected from the group consisting of indomethacin, diclofenac sodium, and ketoprofen.

Abstract: A semi-crystalline, absorbable copolyester composition comprising the reaction product of a polycondensation polyester and at least one lactone, wherein the polycondensation polyester comprises the reaction product of diglycolic acid and/or a derivative thereof and diethylene glycol; and the copolyester comprises about 30 to 60% by weight of the polycondensation polyester based on the total weight of the copolyester. Also medical devices such as absorbable sutures comprising such copolyesters and absorbable microspheres comprising such copolyesters and methods of making of such absorbable microspheres.

Abstract: A method for preventing adhesion using a co-polyester comprising the reaction product of a polycondensation polyester and at least one lactone, wherein the polycondensation polyester comprises the reaction product of diglycolic acid and/or a derivative thereof and ethylene glycol; and the co-polyester comprises about 40 to 50% by weight of the polycondensation polyester based on the total weight of the co-polyester.

Abstract: Copolymers exhibiting the following combinations of properties, including without limitation, ?-caprolactone in an amount ranging from about 12 to about 70 mole percent, glycolide in an amount ranging from about 30 to about 88 mole percent, crystallinity ranging from about 10 to about 50% as measured by WAXD or about 10 to about 50 J/g as measured by DSC, and an inherent viscosity ranging from about 0.5 to about 1.45 dL/g as measured in a 0.1 g/dl solution of HFIP at 25° C.; a method for melt blowing such copolymers and nonwoven constructs produced therefrom are described herein.

Abstract: A bimodal bioabsorbable polymer composition. The composition includes a first amount of a bioabsorbable polymer polymerized so as to have a first molecular weight distribution; a second amount of said bioabsorbable polymer polymerized so as to have a second molecular weight distribution having a weight average molecular weight between about 10,000 to about 50,000 Daltons, the weight average molecular weight ratio of said first molecular weight distribution to said second molecular weight distribution is at least about two to one; wherein a substantially homogeneous blend of said first and second amounts of said bioabsorbable polymer is formed in a ratio of between about 50/50 to about 95/5 weight/weight percent. Also disclosed are a medical device, a method of making a medical device and a method of melt blowing a semi-crystalline polymer blend.

Abstract: A semi-crystalline, absorbable copolyester composition comprising the reaction product of a polycondensation polyester and at least one lactone, wherein the polycondensation polyester comprises the reaction product of diglycolic acid and/or a derivative thereof and diethylene glycol; and the copolyester comprises about 30 to 60% by weight of the polycondensation polyester based on the total weight of the copolyester. Also medical devices such as absorbable sutures comprising such copolyesters and absorbable microspheres comprising such copolyesters and methods of making of such absorbable microspheres. Additionally, a method of melt blowing an absorbable copolyester composition and a nonwoven construct are disclosed.

Abstract: A co-polyester which includes the reaction product of a polycondensation polyester and epsilon-caprolactone, wherein the polycondensation polyester comprises the reaction product of diglycolic acid and/or a derivative thereof and a diol. The co-polyester is injectable and absorbable into animal, such as human, tissue and can be used for facial cosmetic or reconstructive surgery of soft tissue. Another embodiment is directed to a method for preventing adhesion using a co-polyester comprising the reaction product of a polycondensation polyester and epsilon-caprolactone, wherein the polycondensation polyester comprises the reaction product of diglycolic acid and/or a derivative thereof and a diol, and the co-polyester comprises about 40 to 50% by weight of the polycondensation polyester based on the total weight of the co-polyester.

Abstract: A semi-crystalline, absorbable copolyester composition comprising the reaction product of a polycondensation polyester and at least one lactone, wherein the polycondensation polyester comprises the reaction product of diglycolic acid and/or a derivative thereof and diethylene glycol; and the copolyester comprises about 30 to 60% by weight of the polycondensation polyester based on the total weight of the copolyester. Also medical devices such as absorbable sutures comprising such copolyesters and absorbable microspheres comprising such copolyesters and methods of making of such absorbable microspheres.

Abstract: A semi-crystalline, absorbable copolyester composition comprising the reaction product of a polycondensation polyester and at least one lactone, wherein the polycondensation polyester comprises the reaction product of diglycolic acid and/or a derivative thereof and diethylene glycol; and the copolyester comprises about 30 to 50% by weight of the polycondensation polyester based on the total weight of the copolyester.

Abstract: A bimodal bioabsorbable polymer composition. The composition includes a first amount of a bioabsorbable polymer polymerized so as to have a first molecular weight distribution; a second amount of said bioabsorbable polymer polymerized so as to have a second molecular weight distribution having a weight average molecular weight between about 20,000 to about 50,000 Daltons, the weight average molecular weight ratio of said first molecular weight distribution to said second molecular weight distribution is at least about two to one; wherein a substantially homogeneous blend of said first and second amounts of said bioabsorbable polymer is formed in a ratio of between about 50/50 to about 95/5 weight/weight percent. Also disclosed are a medical device and a method of making a medical device.

Abstract: A formulation comprising: a co-polyester comprising (a) the reaction product of a polycondensation polyester and (b) glycolide; wherein the polycondensation polyester comprises the reaction product of diglycolic acid and/or a derivative thereof and ethylene glycol, and the co-polyester comprises about 40% by weight of the polycondensation polyester based on the total weight of the co-polyester; and a drug selected from the group consisting of indomethacin, diclofenac sodium, and ketoprofen.

Abstract: A method for preventing adhesion using a co-polyester comprising the reaction product of a polycondensation polyester and at least one lactone, wherein the polycondensation polyester comprises the reaction product of diglycolic acid and/or a derivative thereof and ethylene glycol; and the co-polyester comprises about 40 to 50% by weight of the polycondensation polyester based on the total weight of the co-polyester.

Abstract: A method for determining the optical retardation and birefringence values of an anisotropic material utilizing a Fourier transform near infrared spectrophotometer operated in at least a portion of the range of wavenumbers between about 4,000 to about 10,000 cm?1.

Abstract: The present invention is directed to a process for making an absorbable polylactone copolymer prepared in part from about 2 to about 80 mole percent glycolide, which process utilizes a combination of a monofunctional polymerization initiator and a di-functional polymerization initiator, to achieve rates of crystallization of the copolymer of at least about 2 times faster than the rate of crystallization of a copolymer made by a similar process utilizing either the mono-functional or the di-functional polymerization initiator alone. Absorbable polylactone copolymers prepared by such processes and medical devices containing such copolymers are also disclosed.

Abstract: The present invention is directed to absorbable polylactone copolymers prepared in part from about 2 to about 80 mole percent glycolide, utilizing a combination of a monofunctional polymerization initiator and a di-functional polymerization initiator, to achieve rates of crystallization of the copolymer of at least about 2 times faster than the rate of crystallization of a copolymer made by a similar process utilizing either the mono-functional or the di-functional polymerization initiator alone. Medical devices containing such copolymers are also disclosed.

Abstract: The present invention is directed to a process for making an absorbable polylactone copolymer prepared in part from about 2 to about 80 mole percent glycolide, which process utilizes a combination of a monofunctional polymerization initiator and a di-functional polymerization initiator, to achieve rates of crystallization of the copolymer of at least about 2 times faster than the rate of crystallization of a copolymer made by a similar process utilizing either the mono-functional or the di-functional polymerization initiator alone. Absorbable polylactone copolymers prepared by such processes and medical devices containing such copolymers are also disclosed.

Abstract: The present invention is directed to absorbable polylactone copolymers prepared in part from about 2 to about 80 mole percent glycolide, utilizing a combination of a monofunctional polymerization initiator and a di-functional polymerization initiator, to achieve rates of crystallization of the copolymer of at least about 2 times faster than the rate of crystallization of a copolymer made by a similar process utilizing either the mono-functional or the di-functional polymerization initiator alone. Medical devices containing such copolymers are also disclosed.

Abstract: The present invention is directed to absorbable, autoclaveable, monofilament fibers prepared from absorbable glycolide-rich polymers, in which the fibers are oriented in the total draw ratio range 4.1 to 5.9X, and are annealed at a temperature between about 165° C. and about 185° C; to brachytherapy seed spacers manufactured from the absorbable, autoclaveable, glycolide-rich polymers, monofilament fibers; and to methods of manufacturing such fibers and brachytherapy seed spacers.